Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImMucin in MUC1-expressing Tumor Malignancies
NCT00162500Phase 2Withdrawn
- Sponsor
- Hadassah Medical Organization
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ImMucin in multiple myeloma (MM), solid tumor, sponsored by Hadassah Medical Organization. Status: withdrawn.
02
Drugs
ImMucin
03
Conditions
multiple myeloma (MM)solid tumor
Beyond the preview
Go deeper on NCT00162500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162500.